

Supplement Table 1: Association of HIF-1, VEGF and MVD with clinicopathological 2 parameters: 3

Clinicopathological variables	HIF-1α (H-score)		Cytoplasmic expression		VEGF (H-score)		Nuclear expression
	Low	High	Low	High	Low	High	
Age	19	25	21	23	19	25	
Below median (n)	9 (47%)	15 (60%)	11 (52.38%)	13 (56.52%)	10 (23%)	14 (32%)	12
Above median (n)	10 (53%)	10 (40%)	10 (47.62%)	10 (43.48%)	9 (20%)	11 (25%)	10
p-value	0.8		0.8		0.8		
Gender							
Female	3 (6.8%)	5 (11%)	3 (6.8%)	5 (11%)	4 (9.1%)	4 (9.1%)	
Male	16 (36%)	20 (45%)	18 (41%)	18 (41%)	15 (34%)	21 (48%)	
p-value	>0.9		0.7		0.7		
Tobacco history							
Absent	2 (11%)	0 (0%)	2 (9.52%)	0 (0.00%)	2 (10.53%)	0 (0.00%)	2
Present	17 (89%)	25 (100%)	19 (90.48%)	23 (100.00%)	17 (89.47%)	25 (100.00%)	20
p-value	0.2		0.2		0.2		
Margin status							
Close and involved	18 (41%)	19 (43%)	16 (36%)	21 (48%)	16 (36%)	21 (48%)	
Free of tumour	1 (2.3%)	6 (14%)	5 (11%)	2 (4.5%)	3 (6.8%)	4 (9.1%)	
p-value	0.12		0.2		>0.9		
Histologic grade							
Well differentiated (G1)	2 (11%)	8 (32%)	4 (19.05%)	6 (26.09%)	3 (15.79%)	7 (28.00%)	6
Moderately differentiated (G2)	11 (58%)	16 (64%)	12 (57.14%)	15 (65.22%)	12 (63.16%)	15 (60.00%)	12
Poorly differentiated (G3)	6 (32%)	1 (4.0%)	5 (23.81%)	2 (8.70%)	4 (21.05%)	3 (12.00%)	4
p-value	0.030*		0.4		0.5		
LVI							
Absent	14 (74%)	17 (68%)	15 (71.43%)	16 (69.57%)	13 (68.42%)	18 (72.00%)	12
Present	5 (26%)	8 (32%)	6 (28.57%)	7 (30.43%)	6 (31.58%)	7 (28.00%)	10
p-value	0.7		0.9		0.8		
PNI							
Absent	12 (63%)	17 (68%)	16 (76.19%)	13 (56.52%)	12 (63.16%)	17 (68.00%)	14
Present	7 (37%)	8 (32%)	5 (23.81%)	10 (43.48%)	7 (36.84%)	8 (32.00%)	8
p-value	0.7		0.2		0.7		
WPOI							
WPOI-1 to 4	12 (63%)	17 (68%)	16 (76.19%)	13 (56.52%)	12 (63.16%)	17 (68.00%)	15
WPOI-5	7 (37%)	8 (32%)	5 (23.81%)	10 (43.48%)	7 (36.84%)	8 (32.00%)	7
p-value	0.7		0.2		0.8		
Tumor stroma ratio							
Stroma poor	5 (11%)	5 (11%)	3 (6.8%)	7 (16%)	5 (11%)	5 (11%)	
Stroma rich	14 (32%)	20 (45%)	18 (41%)	16 (36%)	14 (32%)	20 (45%)	
p-value	0.7		0.3		0.7		
Tumor stage							
pT1,pT2	8 (42.00%)	10 (40.00%)	11 (52.38%)	7 (30.43%)	7 (36.84%)	11 (25%)	8
pT3,pT4	11 (58.00%)	15 (60.00%)	10 (47.62%)	16 (69.57%)	12 (63.16%)	14 (32%)	14
p-value	0.9		0.14		0.6		
N0,N1	13 (68.42%)	19 (76.00%)	17 (80.95%)	15 (65.22%)	16 (84.21%)	16 (64.00%)	15
N2,N3	6 (31.58%)	6 (24.00%)	4 (19.05%)	8 (34.78%)	3 (15.79%)	9 (36.00%)	7
p-value	0.6		0.2		0.14		
Stage I, II	4 (21.05%)	8 (32.00%)	5 (23.81%)	7 (30.43%)	5 (26.32%)	7 (28.00%)	3
Stage III, IV	15 (78.95%)	17 (68.00%)	16 (76.19%)	16 (69.57%)	14 (73.68%)	18 (72.00%)	19
p-value	0.6		0.6		0.9		
P16 status							
Negative	19 (100%)	24 (96%)	21 (100.00%)	22 (95.65%)	19 (43%)	24 (55%)	2
Positive	0 (0%)	1 (4.0%)	0 (0.00%)	1 (4.35%)	0 (0%)	1 (2.3%)	1
p-value	>0.9		>0.9		>0.9		

(Contd...)

Supplement Table 1: (Continued)

Clinicopathological variables	HIF-1 α (H-score)		Cytoplasmic expression		VEGF (H-score)		Nuclear expression
	Low	High	Low	High	Low	High	
Survival							
Alive	15 (78.95%)	16 (64.00%)	15 (71.43%)	16 (69.57%)	5 (26.32%)	7 (28.00%)	14
Dead	4 (21.05%)	9 (36.00%)	6 (28.57%)	7 (30.43%)	14 (73.68%)	18 (72.00%)	8
p-value	0.3		0.9		0.9		
MVD							
Below median	11 (25%)	11 (25%)	15 (34%)	7 (16%)			
Above median	8 (18%)	14 (32%)	6 (14%)	16 (36%)			
p-value	0.4		0.007*				
VEGF							
Below median	8 (42%)	11 (44%)	8 (38.10%)	11 (47.83%)			
Above median	11 (58%)	14 (56%)	13 (61.90%)	12 (52.17%)			
p-value	0.7		0.5				

2 Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test, MVD: microvessel density, HIF-1: hypoxia-inducible factor-1 alpha, VEGF: Vascular endothelial growth factor, WPOI: worst pattern of invasion, LVI: lymphovascular invasion, PNI: perineural invasion, *Significant P-value.